MBL began its history in 1969 as the first Japanese company specializing in the production and supply of antibodies. While maintaining close research and development relationships with academic institutes and pharmaceutical companies, MBL has broadened its basis of operations from immunology to molecular biology and epigenetics. We also provide clinical diagnostics and research reagents for protein and genetic analysis primarily for autoimmune diseases, cancers, gynecologic diseases and infectious diseases. In recent years, MBL has also focused its product development on biomarkers, companion diagnostics and regenerative medicine.

Website: www.mbl.co.jp/e/

« Go Back

Supporting Publication
Organised by
  • Elsevier
  • ISDN
Co-organised by
  • riken